'Sorry, Escape Bio closed': A neurodegenerative upstart exits bid to rival Biogen-Denali
A neurodegenerative disease-focused biotech that was attempting to go up against the billion-dollar pairing of Biogen and Denali has shuttered, Endpoints News has learned.
Escape Bio had built a pipeline of three small molecules for patients with forms of Niemann-Pick Type C, Parkinson’s and Alzheimer’s and wooed a who’s who of biotech investors. Bankrollers included the VC arms of J&J and Novartis, Wellington Capital Management, OrbiMed, Novo Holdings, Sutter Hill Ventures, Surveyor Capital and more than half a dozen others.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.